What a Go-to-Market Strategy Misses When the Market Has Not Formed Yet

A go-to-market strategy fails in medtech when it executes flawlessly against a market that was never defined.

Companies raise capital, get FDA clearance, hire sales, and run marketing, then wonder why none of it converts. The gap isn't execution. It's that category design, messaging, and narrative never happened before go-to-market started.

This shows up the same way across nearly every stalled medtech company I've interviewed. The product works. The clinical data holds up. The go-to-market strategy launches on schedule.

And the pipeline still doesn't move, because the strategy was never given a defined market to execute against in the first place.

I covered this on a recent episode about why medtech founders raise capital without traction: How Market Engineering Helps MedTech Startups Raise Capital.

‍

Key Takeaways

• A go-to-market strategy executes against a category. If the category isn't defined, the strategy has nothing to execute against.
• Most medtech companies skip category design, messaging, and narrative, and jump straight to go-to-market because it feels tangible.
• Clinical validation is not adoption. FDA clearance is not demand. Innovation alone does not create a category.
• When go-to-market underperforms, sales blames awareness. The real gap is upstream, in how the market was defined.
• Market engineering comes first, starting with category and messaging. Go-to-market comes last, and only works once the earlier work exists.

‍

Why Medtech Founders Build a Go-to-Market Strategy Before the Category Exists

Most medtech founders follow the same sequence. Engineer the product, get FDA clearance, hire sales, run marketing.

That sequence has discipline built into every step except one. There's no equivalent rigor applied to defining the market the product will sell into.

I explained the timing problem directly on the episode about raising capital:

"A key question I often get asked is when should you think about defining a category? And it's definitely before you think about go-to-market or scaling it. If you wait, which a lot of companies have, they go to market, and they pretty much scale confusion."

Founders treat category definition as a nice-to-have. So they build the go-to-market strategy first and plan to figure out positioning along the way.

That's backward. The category sets the rules of the game the go-to-market strategy has to play by.

How Category Design Should Sequence Before Any Go-to-Market Strategy Launches

Market engineering breaks into four parts: category, messaging, narrative, and go-to-market. Most medtech companies skip the first three and go straight to the fourth.

I broke down why on an episode about technology adoption in medtech:

"Every medtech company skips those first three steps, goes straight to go-to-market. And it makes sense, because go-to-market is a tangible thing. I hire sales, I hire marketing, and that's good. The problem is that when you do that, you're not executing against an engineered market, and you struggle."

A go-to-market strategy built without category work isn't wrong. It's incomplete. Sales and marketing execute against something, but that something was never designed with the same discipline the product got.

On the same episode, I named exactly what breaks first:

"The go-to-market is not executing against something that was designed and engineered and architected with the same level of discipline as when it came to the product."

That mismatch shows up fast. Marketing gets judged on different KPIs than sales, so the strain lands hardest on the sales team.

In medtech specifically, marketing rarely means just marketing. The function often absorbs product management, KOL relationships, and clinical education work that gets split across separate teams in other industries. So when a go-to-market strategy underperforms, the diagnosis gets muddled across departments that don't share the same definition of the problem.

That confusion is itself a symptom. A defined category gives every function, sales, marketing, and clinical, the same shared language for what's being sold and why it matters. Without it, each team ends up solving a different version of the same underlying gap.

What Happens When a Go-to-Market Strategy Competes Against an Undefined Category

Skipping category design slows a go-to-market strategy down, and it puts the company in a fight it can't win.

I've watched well-funded medtech companies run this exact play. On the same episode about raising capital, I described what happens next:

"There's plenty of companies in our space who've raised hundreds of millions of dollars, a couple of them over a billion dollars, and they have nothing to show. Literally nothing. They did not think about designing or redesigning their category against the incumbent. So guess what happens? The market compares and evaluates that company against the category leader. And you lose every single time."

A go-to-market strategy without a defined category doesn't create a new market. It defaults into competing against the incumbent on the incumbent's terms, using the incumbent's language, in a category the incumbent already owns.

That's a fight funding can't fix. The company with the bigger budget and the better product still loses, because the buyer has no framework for evaluating them as anything other than a smaller, riskier version of the market leader.

Category design breaks that comparison. It gives the go-to-market strategy a different game to play, one where the company sets the terms instead of inheriting someone else's.

I've seen founders discover this the hard way after a Series B raise, once the board starts asking why growth has plateaued despite continued investment in sales and marketing.

The honest answer is rarely "we need a bigger team." It's that the go-to-market strategy has been fighting the wrong fight since launch, and no amount of budget changes the terms of a comparison the company never got to define.

The companies that break out of this pattern usually do one thing differently. They stop the go-to-market strategy, go back and do the category work that should have come first, and relaunch with a defined market instead of an inherited one.

That pause feels like lost time in the moment. It's usually the fastest path back to growth.

Why Sales Blames Awareness When a Go-to-Market Strategy Underperforms

When a go-to-market strategy isn't converting, sales rarely blames the category. Sales says there isn't enough market awareness, and asks for more marketing.

That instinct isn't wrong, but it's aimed at the wrong fix. More campaigns against an undefined category produce more education calls, not more closed deals.

I've watched this exact pattern across 400+ episodes of State of MedTech. Founders with strong clinical data and real funding still stall, because clinical proof was never the constraint.

I opened an episode with Nick Damiano, founder of Andromeda Surgical, with this:

"Most medtech companies don't fail because the product doesn't work. They fail because the market never really forms around them. Clinical validation is not adoption. FDA clearance is not demand. And innovation alone does not create a category."

A go-to-market strategy can't manufacture the demand that category design was supposed to build first.

This is why adding headcount rarely fixes a stalled go-to-market strategy. A new sales rep still has to explain the category from scratch on every call, and a new marketing hire still has to build messaging without a defined narrative to build it from. The team grows, but the underlying problem doesn't move.

I see founders interpret slow pipeline as a hiring problem when it's a definition problem. The remedy isn't more people executing the same undefined strategy faster. It's stopping to do the category work the go-to-market strategy was missing from the start.

What Medtech Founders Should Sequence Before Writing a Go-to-Market Strategy

The remedy isn't a bigger go-to-market budget. It's building the three steps that should come before it.

Category design names the market the way the ICP already recognizes it, or redefines the market against the incumbent standard. Messaging translates that category into language buyers use. Narrative builds the proof, clinical and economic, that makes the category credible.

I explained the underlying issue on the same capital-raising episode:

"Most MedTech founders don't exactly have a demand problem. What they have is really a definition problem. Until you define a market clearly, you're not able to get any traction."

Once those three pieces exist, a go-to-market strategy has something real to execute against. The sales team stops improvising positioning on every call, and the marketing budget stops paying for awareness a defined category would have created for free.

This connects to the same sequencing problem covered in why medical device go-to-market decisions should follow a Series A to acquisition timeline and the five pillars of market engineering every medtech founder should know.

What This Means for Medtech Founders

In my experience working with medtech founders, the go-to-market strategy conversation happens too early almost every time. Founders want a go-to-market plan because it feels like the finish line after years of product development.

But a go-to-market strategy is the last step in market engineering, after category and narrative. Skipping ahead to it doesn't save time. It just moves the same unresolved category work downstream, where it costs more to fix.

Before writing a go-to-market strategy, I ask founders one question: can a buyer explain, in their own words, what category this product belongs to and why it matters right now? If the answer is no, the go-to-market strategy has nothing solid to stand on yet.

Once the category, messaging, and narrative exist, go-to-market becomes the easiest part of the whole sequence.

I've watched this play out in reverse, too. Companies that do the category work first spend less on their eventual go-to-market strategy, not more, because they aren't paying campaigns to do the education work category design should have handled.

The budget goes toward reinforcing a message the market already half-believes instead of introducing an idea from zero.

That's the real cost of sequencing go-to-market before category design. It's spending more to get a worse outcome, twice, once on the go-to-market strategy that failed and again on the category work that had to happen anyway.

There's also a credibility cost that's harder to measure but just as real. A go-to-market strategy that launches, underperforms, and gets reworked six months later signals to the board, the sales team, and the market itself that the company doesn't fully understand its own positioning. That signal is expensive to undo, and it compounds every time the cycle repeats.

Founders who do the category work up front avoid that cycle entirely. The go-to-market strategy they launch is the one they keep, because it was built against a market that was already defined rather than one still being discovered in real time through trial and error in the field.

Frequently Asked Questions

What is the difference between a go-to-market strategy and market engineering?

A go-to-market strategy covers the tactics that generate sales and demand once a market exists: hiring, campaigns, and channel selection.

Market engineering is the upstream work of category design, messaging, and narrative that a go-to-market strategy needs in order to convert. One is execution. The other is the definition that execution depends on.

Why does a go-to-market strategy fail even with FDA clearance and strong clinical data?

FDA clearance and clinical data prove the product works. They don't prove the market understands what category the product belongs to or why it matters. A go-to-market strategy executed against an undefined category produces awareness without adoption.

When should a medtech founder build a go-to-market strategy?

After category design, messaging, and narrative are in place. Building a go-to-market strategy earlier means sales and marketing improvise positioning on every call instead of executing against a market that already understands the category.

How does a go-to-market strategy fail against an established competitor?

Without a defined category, buyers default to comparing the new company against the incumbent using the incumbent's own criteria. A go-to-market strategy built on category design changes what the buyer is comparing against, instead of asking a smaller company to win on the market leader's terms.

Listen to the Full Conversations

I covered the market engineering sequence on How Market Engineering Helps MedTech Startups Raise Capital. I broke down technology adoption and go-to-market discipline on How MedTech Startups Drive Technology Adoption to Cross the Chasm and Scale.

And I opened my conversation with Nick Damiano, founder of Andromeda Surgical, on Autonomous Surgery and the Future of Robotics. Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, one of the leading podcasts in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.